Evidence map›Paper›PMID 41058627›Full record

ArticleFrontiers in medicine2025

Anti-

Shomi Oka, Takashi Higuchi, Kota Shimada, Misuzu Fujimori, Atsushi Hashimoto, Akiko Komiya, Koichiro Saisho, Norie Yoshikawa, Michita Suzuki, Toshihiro Matsui and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shomi OkaDepartment of Rheumatology, NHO Tokyo National Hospital, Kiyose, Japan.
Takashi HiguchiDepartment of Rheumatology, NHO Tokyo National Hospital, Kiyose, Japan.
Kota ShimadaDepartment of Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
Misuzu FujimoriDepartment of Rheumatology, NHO Himeji Medical Center, Himeji, Japan.
Atsushi HashimotoDepartment of Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
Akiko KomiyaClinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
Koichiro SaishoDepartment of Orthopedics/Rheumatology, NHO Miyakonojo Medical Center, Miyakonojo, Japan.
Norie YoshikawaTanimura Hospital, Nobeoka, Japan.
Michita SuzukiDepartment of Internal Medicine, NHO Nagoya Medical Center, Nagoya, Japan.
Toshihiro MatsuiClinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
Naoshi FukuiClinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
Kiyoshi MigitaClinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
Shigeto TohmaDepartment of Rheumatology, NHO Tokyo National Hospital, Kiyose, Japan.
Hiroshi FurukawaDepartment of Rheumatology, NHO Tokyo National Hospital, Kiyose, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti- Methods: Anti- Results: Anti- Conclusion: Anti-

Indexed as

anti-Porphyromonas gingivalis antibodieschronic lung diseasecitrullinated peptidesemphysemarheumatoid arthritis

Identifiers

PMID41058627
PMCPMC12497748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.